Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

C4 Therapeutics (CCCC) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to 0.1%.

  • C4 Therapeutics' Return on Capital Employed fell 200.0% to 0.1% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1%, marking a year-over-year decrease of 200.0%. This contributed to the annual value of 0.38% for FY2024, which is 100.0% up from last year.
  • C4 Therapeutics' Return on Capital Employed amounted to 0.1% in Q3 2025, which was down 200.0% from 0.09% recorded in Q2 2025.
  • In the past 5 years, C4 Therapeutics' Return on Capital Employed ranged from a high of 0.05% in Q4 2021 and a low of 0.1% during Q3 2025
  • In the last 5 years, C4 Therapeutics' Return on Capital Employed had a median value of 0.08% in 2024 and averaged 0.08%.
  • In the last 5 years, C4 Therapeutics' Return on Capital Employed surged by 2200bps in 2021 and then crashed by -400bps in 2023.
  • Quarter analysis of 5 years shows C4 Therapeutics' Return on Capital Employed stood at 0.05% in 2021, then plummeted by -51bps to 0.07% in 2022, then crashed by -39bps to 0.09% in 2023, then rose by 14bps to 0.08% in 2024, then fell by -28bps to 0.1% in 2025.
  • Its last three reported values are 0.1% in Q3 2025, 0.09% for Q2 2025, and 0.08% during Q1 2025.